EPOPROSTENOL ( DrugBank: Epoprostenol )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	23

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 23 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-142722	01/1/2015	27/11/2014	ACT-385781A extension study for PAH pediatric patients	Open-label, long-term, efficacy, safety, and tolerability extension study using ACT-385781A in the t ...	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	3	Phase 3	NULL
2	JPRN-JapicCTI-142721	01/9/2014	27/11/2014	ACT-385781A for PAH pediatric patients	Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerab ...	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	3	Phase 3	NULL
3	JPRN-JapicCTI-132142	01/4/2013	03/06/2013	ACT-385781A PAH Post-marketing study	A Post-marketing, Open-label-study ACT-385781A in patients with pulmonary arterial hypertension	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : Epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL		20		BOTH	5	Phase 4	NULL
4	EUCTR2010-018320-10-ES (EUCTR)	26/12/2011	21/11/2011	An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epo ...	An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A ...	Hipertension Arterial Pulmonar MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pul ...	Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	40		France;Canada;Belgium;Spain;Netherlands;Italy
5	EUCTR2011-002943-92-NL (EUCTR)	07/11/2011	22/08/2011	Study of a new thermostable formulation of Flolan™ to treat Pulmonary Arterial Hypertension (PAH)	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	pulmonary arterial hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ...	Trade Name: FLOLAN™ and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 I ...	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	20		United States;Canada;Netherlands
6	EUCTR2010-018320-10-IT (EUCTR)	04/11/2011	01/03/2012	An extension of study AC-066A301 to investigate safety and tolerabilityof the study medication (epop ...	Estensione in aperto dello studio AC-066A301 per valutare la sicurezza e la tollerabilita' dell’ACT- ...	Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ...	Trade Name: Epoprostenolo per iniezione INN or Proposed INN: EPOPROSTENOLSODIUM Other descriptive name ...	Actelion Pharmaceuticals Ltd.	NULL	Not Recruiting			Female: yes Male: yes	40		Canada;Spain;Belgium;Netherlands;Italy
7	NCT01462565 (ClinicalTrials.gov)	November 1, 2011	13/10/2011	Study of a New Thermo Stable Formulation of EpoprostenolSodium to Treat Pulmonary Arterial Hypertens ...	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	Hypertension, Pulmonary	Drug: current marketed FLOLAN (epoprostenolsodium);Drug: new thermo stable formulation of epoprosten ...	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	16	Phase 4	United States;Canada;Netherlands
8	JPRN-JapicCTI-122017	01/8/2011	03/12/2012	ACT-385781A PAH	Open-label study ACT-385781A in patients with pulmonary arterial hypertension	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL		20		BOTH	10	Phase 3	NULL
9	EUCTR2010-018320-10-NL (EUCTR)	11/07/2011	12/05/2011	An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epo ...	An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A ...	Pulmonary Arterial Hypertension MedDRA version: 14.1;Level: PT;Classification code 10064911;Term: Pu ...	Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	40		France;Canada;Belgium;Spain;Netherlands;Italy
10	EUCTR2010-018322-40-NL (EUCTR)	11/07/2011	19/07/2011	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan ...	Pulmonary Arterial Hypertension MedDRA version: 12.1;Level: LLT;Classification code 10064911;Term: P ...	Trade Name: Epoprostenolfor injection Product Name: Epoprostenolfor injection Product Code: ACT-385781 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 3	Netherlands;Belgium;France;Spain;Italy

First Previous1 2 3Next Last